1. Home
  2. EMAT vs WGS Comparison

EMAT vs WGS Comparison

Compare EMAT & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evolution Metals & Technologies Corp. Common Stock

EMAT

Evolution Metals & Technologies Corp. Common Stock

BUY

Current Price

$1.44

Market Cap

2.6B

Sector

N/A

ML Signal

BUY

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$58.18

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMAT
WGS
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
EMAT
WGS
Price
$1.44
$58.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$8.25
★ $93.50
AVG Volume (30 Days)
★ 1.3M
643.6K
Earning Date
08-17-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 62.37
EPS
★ N/A
N/A
Revenue
N/A
★ $427,539,000.00
Revenue This Year
N/A
$12.70
Revenue Next Year
$1,102.50
$24.31
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 39.97
52 Week Low
$1.28
$32.21
52 Week High
$17.50
$170.87

Technical Indicators

Market Signals
Indicator
EMAT
WGS
Relative Strength Index (RSI) 29.96 32.45
Support Level $1.28 $56.36
Resistance Level $2.26 $73.04
Average True Range (ATR) 0.20 5.31
MACD 0.02 -0.35
Stochastic Oscillator 14.80 8.86

Price Performance

Historical Comparison
EMAT
WGS

About EMAT Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp is a critical materials and technology company. The company is focused on developing a secure, dependable, and self-sustaining U.S.-aligned supply chain for critical minerals and materials (CMM), and rare earth elements (REEs). The company is also engaged in recycling end-of-life materials through urban mining to help strengthen domestic resource independence and long-term supply stability.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: